3-way replicate vs. 4-way [GxP / QC / QA]

posted by drmuneesh – 2009-08-17 07:46 (6158 d 20:05 ago) – Posting: # 4049
Views: 10,837

Dear HS

Thank you for the reply. We are planning 4-period replicate design to reduce the number of subjects also. Highly variable drug like risedronate having intrasubject variability of 50-80% would require too many subjects in case of 3-period design. 3-period design may be ok for drugs having intrasubject variability of 30-50%.

Please suggest if I am wrong.

Regards

Dr Muneesh Garg

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
210 visitors (0 registered, 210 guests [including 28 identified bots]).
Forum time: 03:51 CEST (Europe/Vienna)

The real struggle is not between the right and the left
but between the party of the thoughtful
and the party of the jerks.    Jimmy Wales

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5